AIM ImmunoTech said it will work with its contract research organization, Amarex Clinical Research LLC, to seek FDA fast-track and possibly breakthrough designations and to obtain investigational new drug authorizations to conduct a follow-up pancreatic cancer Phase 2/3 clinical trial. Such a trial would have sites in the Netherlands led by van Eijck, as well as, at major cancer research centers in the US.
Jerry1979
Bullish
@wallstreet777 When can we expect fda approval for pankreatic cancer? Is it that one they mentioned fast track and or breakthrough?
View original message
  • 1
1 Like